Open Access Research Article Article ID: OJPDT-3-108

    Parkon® in the treatment of multiple sclerosis. A pilot study

    Goldstein NI, Golubev VL and Goldstein RN*

    Multiple Sclerosis (MS) is one of the most common chronic demyelinating diseases of the central nervous system. The disease affects and relatively quickly leads to disability in mainly people 15-40 years of age. The development of MS can occur progressively or with exacerbations and remissions. The pathogenesis of the disease is based on an autoimmune process directed against myelin or myelin-producing CNS oligodendrocytes. In recent years, in the mechanisms of death of myelin-synthesizing oligodendrocytes, more and more attention has been paid to metabolic shifts. An important role is played by the activation of astro- and microglia, impaired neurotransmitter metabolism and apoptosis


    Published on: Aug 7, 2020 Pages: 1-5

    Full Text PDF Full Text HTML DOI: 10.17352/ojpdt.000008
    CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat


    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on OJPDT

    Help ? Google Reviews 11